ArticleTranslational cancer research2019
Clinicopathologic characteristics and survival analysis in stage IVB cervical cancer with hematogenous metastasis.
Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Unlocking the potential of immune checkpoint inhibitors in advanced cervical cancer: a meta-analysis and systematic review.BMC cancer · 2025Pooled it
- Primary malignant melanoma of the female urethra: a case report and literature review.The Canadian journal of urology · 2026Review
- HPV16 E6 regulates the proliferation, invasion, and apoptosis of cervical cancer cells by downregulating miR-504.Translational cancer research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study was to analyze the clinical characteristics, treatment modalities and prognosis of stage IVB cervical cancer patients with hematogenous metastasis.
methodsBetween March 2005 and December 2017, a total of 160 patients FIGO (International Federation of Gynecology and Obstetrics, version 2018) stage IVB cervical cancer patients with hematogenous metastasis were included in this retrospective study. Patients were excluded from this analysis if they had lymphatic metastasis alone. Survival analyses included the Kaplan-Meier method, log-rank test, and Cox proportional hazards model.
resultsAmong 160 patients with hematogenous metastasis, 78 patients (48.8%, 78/160) exhibited only hematogenous metastases, while 82 (51.3%, 82/160) exhibited distant organ and lymph node (LN) metastases. Bone (37.5%, 60/160) was the most frequent metastatic site compared to lung (23.1%, 37/160) and liver (12.5%, 20/160). The median duration overall survival (OS) was 26 months and the 3-year OS rate was 35.3%. In univariate analysis, a significant difference was found in prognostic factors related to OS including tumor size (P=0.030), histology (P=0.006), white blood cell (WBC) count (P<0.001), squamous cell carcinoma antigen (SCCA) level (P=0.026), numbers of distant metastasis (P=0.017) and primary treatment (P=0.015). In multivariate analysis, the WBC was reported as an independent risk factor of progression free survival (PFS) (P=0.012, HR =3.25, 95% CI, 1.30-8.14) and OS (P=0.000, HR =6.18, 95% CI, 2.39-15.95). In addition, chemoradiotherapy was found to prolong the OS of stage IVB cervical cancer patients with hematogenous metastasis (32
conclusionsFor stage IVB cervical cancer with hematogenous metastasis, the WBC count was an independent recurrence and death risk factor. Also, stage IVB cervical cancer patients with hematogenous metastasis should not be treated with systemic chemotherapy alone, palliative radiotherapy should also be integrated into the treatment plan. However, future large scale prospective clinical trial was desperately in need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.